Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial - Concepedia

Concepedia

Publication | Open Access

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

DOI Full Paper Access

128

Citations

14

References

2019

Year

Michael G. Hanna, Umesh A. Badrising, Olivier Benvéniste, Thomas E. Lloyd, Merrilee Needham, Hector Chinoy, Masashi Aoki, Pedro Machado, Christina Liang, Katrina Reardon,

The Lancet Neurology

Autoimmune DiseaseImmunologyPlacebo-controlled Phase 2BImmunotherapyMedicineIntravenous BimagrumabInclusion Body Myositis

References

	Year	Citations

Page 1

Page 1